Squarepoint’s Recursion Pharmaceuticals RXRX Stock Holding History

Squarepoint’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$361K	Buy	98,426 +45,438	+86%	+$151K	﹤0.01%	3681
2026 Q1	$163K	Sell	52,988 -834,016	-94%	-$3.22M	﹤0.01%	3999
2025 Q4	$3.63M	Buy	+887,004	New	+$4.39M	﹤0.01%	1661
2025 Q3	–	Sell	-24,091	Closed	-$122K	–	4907
2025 Q2	$122K	Sell	24,091 -92,368	-79%	-$454K	﹤0.01%	4119
2025 Q1	$616K	Buy	116,459 +36,038	+45%	+$263K	﹤0.01%	3105
2024 Q4	$544K	Buy	+80,421	New	+$541K	﹤0.01%	3658
2024 Q2	–	Sell	-131,849	Closed	-$1.31M	–	4567
2024 Q1	$1.31M	Buy	+131,849	New	+$1.47M	﹤0.01%	2379
2023 Q4	–	Sell	-161,816	Closed	-$1.24M	–	4425
2023 Q3	$1.24M	Buy	161,816 +37,842	+31%	+$378K	﹤0.01%	2164
2023 Q2	$926K	Sell	123,974 -66,411	-35%	-$465K	﹤0.01%	2215
2023 Q1	$1.27M	Buy	190,385 +120,585	+173%	+$957K	0.01%	1730
2022 Q4	$538K	Buy	+69,800	New	+$684K	﹤0.01%	2233
2022 Q2	–	Sell	-56,332	Closed	-$403K	–	3302
2022 Q1	$403K	Sell	56,332 -1,125	-2%	-$12K	﹤0.01%	2126
2021 Q4	$984K	Buy	+57,457	New	+$1.08M	﹤0.01%	1707

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Squarepoint's RXRX Position: Q2 2026 in Review

Squarepoint increased its Recursion Pharmaceuticals (RXRX) stake by 86% in Q2 2026, buying an estimated $151K and bringing the position to 98,426 shares worth $361K. The position accounts for ﹤0.01% of the portfolio, ranked #3681.

Squarepoint first reported a position in RXRX in Q4 2021 and has held it in 13 quarters since. The position peaked at $3.63M in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Squarepoint held 98,426 shares of Recursion Pharmaceuticals worth $361K as of Q2 2026.
Squarepoint bought 45,438 Recursion Pharmaceuticals shares in Q2 2026, an estimated $151K.
Recursion Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3681 holding.
Squarepoint first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
Squarepoint's Recursion Pharmaceuticals position peaked at $3.63M in Q4 2025.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.